Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ChAd3-EBO-Z Ebola vaccine in African children
2014-004714-28Phase 2
- Sponsor
- GSK
- Start
- Sep 2015
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ChAd3-EBO-Z in Ebola virus disease (EVD) (2 arms), sponsored by GSK. Primary endpoint: Occurrence of each solicited local and general adverse event.
02
Drugs
ChAd3-EBO-Z
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on 2014-004714-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004714-28.